New England Journal of Medicine publishes exploratory study showing signals of positive activity in COMP360 psilocybin compared with escitalopram for major depressive disorderGlobeNewsWire • 04/15/21
COMPASS Pathways plc to participate in 20th Annual Needham Virtual Healthcare ConferenceGlobeNewsWire • 04/09/21
COMPASS Pathways plc announces financial results and business highlights for fourth quarter and year-end 2020GlobeNewsWire • 03/09/21
COMPASS Pathways plc to announce fourth quarter and full year 2020 financial results on 9 March 2021GlobeNewsWire • 03/02/21
COMPASS Pathways plc to participate in Cowen's 41st Annual Health Care ConferenceGlobeNewsWire • 02/26/21
COMPASS Pathways expands its Discovery Center through new collaborations with world-leading scientistsGlobeNewsWire • 02/09/21
COMPASS Pathways announces publication in Frontiers in Psychiatry of paper on therapist training programme for psilocybin therapyGlobeNewsWire • 02/03/21
Correction: COMPASS Pathways establishes Centre of Excellence with Sheppard Pratt to accelerate research and improve patient experience in mental health careGlobeNewsWire • 01/08/21
COMPASS Pathways establishes Centre of Excellence with Sheppard Pratt to accelerate research and improve patient experience in mental health careGlobeNewsWire • 01/08/21
COMPASS Pathways plc to participate in HC Wainwright and ICR investor conferencesGlobeNewsWire • 01/06/21
Psilocybin Will Change Mental Health, Compass Pathways Could Be At The ForefrontSeeking Alpha • 01/01/21